Vestor Capital LLC Cuts Stock Position in AbbVie Inc. $ABBV

Vestor Capital LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 83.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,770 shares of the company’s stock after selling 369,951 shares during the quarter. AbbVie accounts for approximately 1.1% of Vestor Capital LLC’s investment portfolio, making the stock its 27th biggest position. Vestor Capital LLC’s holdings in AbbVie were worth $15,609,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie in the fourth quarter valued at approximately $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie in the fourth quarter worth $31,000. Legacy Wealth Managment LLC ID raised its stake in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC boosted its holdings in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of ABBV opened at $257.57 on Friday. The firm has a fifty day moving average price of $238.39 and a 200 day moving average price of $223.86. The stock has a market cap of $455.07 billion, a PE ratio of 126.88, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. AbbVie Inc. has a 1-year low of $187.62 and a 1-year high of $267.47.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.46 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.14 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 340.89%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Canaccord Genuity Group upped their price target on AbbVie from $273.00 to $282.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Bank of America boosted their price objective on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. BMO Capital Markets lifted their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Piper Sandler reissued an “overweight” rating and issued a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $269.29.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved RINVOQ® for severe alopecia areata in adults and adolescents aged 12 and older. The Phase 3 program demonstrated statistically significant scalp, eyebrow, and eyelash hair regrowth, including complete scalp regrowth for some patients. The approval expands RINVOQ’s commercial opportunity in Europe. RINVOQ alopecia areata approval
• Positive Sentiment: RINVOQ also received EU approval for non-segmental vitiligo, making it the first and only systemic treatment approved for that condition in the region. The decision was supported by positive Phase 3 repigmentation data and could further diversify RINVOQ growth. RINVOQ vitiligo approval
• Positive Sentiment: AbbVie began a first-in-human Phase 1 trial of ABBV-859, providing an early-stage pipeline catalyst. The program is not expected to affect near-term earnings, but investors may view it as evidence of continued investment in long-term growth. ABBV-859 Phase 1 trial
• Positive Sentiment: Unusually heavy call-option buying and a modest increase in an analyst’s 2027 earnings forecast indicate that some traders and analysts remain bullish on AbbVie’s longer-term earnings outlook.
• Neutral Sentiment: Allergan Aesthetics will hold its annual JUVÉDERM® Day on August 19, supporting consumer engagement and the aesthetics franchise, although the promotional event is unlikely to materially change near-term financial results. JUVÉDERM Day announcement
• Neutral Sentiment: Investors are also focused on AbbVie’s second-quarter earnings report due July 31. A slight reduction in one 2026 earnings estimate was offset by a higher 2027 forecast, leaving expectations mixed ahead of the report.
• Negative Sentiment: AbbVie’s proposed acquisition of Apogee Therapeutics faces an investigation into the deal’s price and transaction process. While the review does not establish wrongdoing, it introduces regulatory and execution uncertainty around the transaction. Apogee transaction investigation
• Negative Sentiment: After a strong multi-year rally, valuation concerns and potential profit-taking may be pressuring ABBV, particularly with the shares trading near their 52-week high and at a rich earnings multiple.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.